Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 | MicrobiomeTrials← Back to trialsNCT04591483
Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4
RecruitingOBSERVATIONAL
Trial Details
Start: 2022-04-19Est. Completion: 2028-07-16
Enrollment target: 25 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Stargardt DiseaseStargardt Macular DystrophyStargardt-like Macular Dystrophy
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the r…
Phoenix, United StatesEst. completion Jul 31, 2028
Stargardt Disease Type 1 (STGD1)
Stargardt disease type 1 (STGD1) is a rare genetic eye condition that causes progressive vision loss, often beginning in…
Shanghai, ChinaEst. completion Feb 28, 2027